RT Journal Article
SR Electronic
T1 Intravenous Antibiotics in Preterm Infants have a Long-Term Negative Effect upon Microbiome Development Throughout Preterm Life – an observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.29.22280493
DO 10.1101/2022.09.29.22280493
A1 Hutchinson, RA
A1 Costeloe, KL
A1 Wade, WG
A1 Millar, MR
A1 Ansbro, K
A1 Stacey, F
A1 Fleming, PF
YR 2022
UL http://medrxiv.org/content/early/2022/10/04/2022.09.29.22280493.abstract
AB Intestinal dysbiosis is implicated in the origins of necrotising enterocolitis and late-onset sepsis in preterm babies. However, the effect of modulators of bacterial growth (e.g. antibiotics) upon the developing microbiome is not well-characterised.Using high-throughput 16S rRNA gene sequencing combined with contemporaneous clinical data collection, the within-subject relationship between antibiotic administration and microbiome development was assessed, in comparison to preterm infants with minimal antibiotic exposure.During courses of antibiotics, diversity progression fell in comparison to that seen outside periods of antibiotic use (−0.71units/week vs. +0.63units/week, p<0.01); Enterobacteriaceae relative abundance progression conversely rose (+10.6%/week vs. -8.9%/week, p<0.01). After antibiotic cessation, diversity progression remained suppressed (+0.2units/week, p=0.02).Antibiotic use has an acute and longer-lasting impact on the developing preterm intestinal microbiome. This has clinical implications with regard to the contribution of antibiotic use to evolving dysbiosis, and affects the interpretation of existing microbiome studies where this effect modulator is rarely accounted for.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work leading to this publication would not have been possible without the generous support of Barts Charity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the London (Chelsea) Research Ethics Committee (Ref: 15/LO/1924).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. The raw sequencing data and metadata were uploaded to a publicly accessible database (The NCBI Sequence Read Archive) under the BioProject accession code PRJNA605031.